Is TMDX stock a Buy, Sell, or Hold?

Based on our analysis, TMDX is currently a WAIT with low confidence. 📊 MIXED SIGNALS: TMDX shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of TMDX stock?

Our analysis estimates the fair value range for TMDX to be between $82.85 and $91.93. The current price is $82.18.

What is the analyst price target for TMDX?

The average Wall Street analyst price target for TMDX is $97.30. This implies a potential upside of 18.4% from current levels.

TransMedics Group (TMDX) Stock: Buy, Sell, or Hold?

TMDX - TransMedics Group, Inc. Common Stock

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

$82.18

-2.86 (-3.36%) ▼

5d: -5.52%

30d: -5.56%

90d: +11.67%

WAIT

LOW Confidence

Protect Your TMDX Gains

Analysis Updated: Sep 11, 2026 12:00 AM ET

Earnings: Nov 04, 2026

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Sep 4, 2026 at $89.98 · last confirmed Sep 9, 2026

Strength: 8.1/10

Get Alerted When TMDX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: TMDX shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$111.73

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$69.38

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: TMDX is currently trading at $82.18, which is considered oversold relative to its 30-day fair value range of $82.85 to $91.93. The stock's valuation (Forward PE: 35.8) is in line with its historical norms (33.2). At these levels, the market is pricing in 2.6% annual earnings growth.

Technical Outlook: Technically, TMDX is showing sideways momentum. Immediate support is located at $79.23, while resistance sits at $93.45. Short-term momentum is weak, with the stock down 3.4% recently.

Market Sentiment: TMDX scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $97.30 (+18.4%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $82.85 - $91.93

Company Quality Score 38/100 (SELL)

Volume Confirmation HIGH

Confidence Score 53.3%

Protect Your Profits

Holding TMDX? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (16/100)
BULLISH: High volume confirmation
BEARISH: Downward momentum (-3.4%)
BULLISH: Trading below Wall St target ($97.30)
BULLISH: Expecting earnings turnaround to 2.6% growth with 20.7% revenue growth
WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $82.85 - $91.93

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $79.23

Resistance Level $93.45

Current Trend Sideways

Technical data as of Sep 11, 2026

Fundamental Context

Forward P/E (Next Year Est.) 35.81

Wall Street Target $97.30 (+18.4%)

Revenue Growth (YoY) 20.7%

Earnings Growth (YoY) -55.8%

Profit Margin 22.7%

Valuation Premium vs History +2.6% premium

PE vs Historical 35.8 vs 33.2 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +2.6% (market-implied from PE analysis)

1-Year Target $84.32 (+3%)

2-Year Target $86.51 (+5%)

3-Year Target $88.76 (+8%)

3-Yr Target (if PE normalizes) (PE: 36→33) PE COMPRESSION $82.29 (+0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 35.8, Growth: 50.9%) $277.36 (+238%)

Base: (SPY PE: 20.2, Growth: 50.9%) $156.23 (+90%)

Bear: (PE: 17.1, Growth: 50.9%) $132.79 (+62%)

📈 Valuation based on Current Earnings

Trailing PE: 22.38 | Current EPS (TTM): $3.80

Bull Case $56.50 (-31%)

Analyst growth -39.6%, PE expands to 24.6

Base Case $51.36 (-38%)

Market implied -39.6%, PE stable at 22.4

Bear Case $57.83 (-30%)

Severe decline -20.0%, PE contracts to 19.0

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: September 12, 2026 12:54 PM ET
Data refreshes hourly during market hours. Next update: 1:54 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is TMDX showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for TMDX.

Create Free Account

Already have an account? Log In

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
BSX Boston Scientific Corp	STRONG BUY 34 analysts	$63	49 HOLD
DXCM DexCom Inc	STRONG BUY 27 analysts	$94	40 HOLD
SYK Stryker Corporation	BUY 32 analysts	$383	44 HOLD
MDT Medtronic PLC	BUY 32 analysts	$105	52 HOLD
PODD Insulet Corporation	STRONG BUY 24 analysts	$172	41 HOLD

BSX Boston Scientific…

49 HOLD

DXCM DexCom Inc

40 HOLD

SYK Stryker Corporati…

44 HOLD

MDT Medtronic PLC

52 HOLD

PODD Insulet Corporati…

41 HOLD

Advanced TMDX Option Strategies

Professional options setups generated by AI based on today's TMDX price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for TMDX

TMDX Technical Chart TMDX Price Prediction TMDX Earnings Date Why is TMDX Moving Today? TMDX Investment Advisor TMDX Fair Price Analyzer TMDX Options Advisor TMDX Options Chain TMDX Options Analysis TMDX Competitors

Compare TMDX with Peers

TMDX vs OSCR
Which one to buy?

TMDX vs CELH
Which one to buy?

TMDX vs FOUR
Which one to buy?

TMDX vs CLPT
Which one to buy?

TMDX vs DLO
Which one to buy?

TMDX vs INSP

TMDX vs HAE

MDT vs TMDX

TMDX vs ATEC
Winner: TMDX

TXG vs TMDX
Winner: TXG

EDAP vs TMDX

Create New Comparison View All Competitors

Tradestie